Chemotherapy efficacy in metastatic neuroendocrine colorectal cancer

AIM: to evaluate the effectiveness of first-line chemotherapy in patients with colorectal neuroendocrine cancer (NEC). PATIENTS AND METHODS: a retrospective study included metastatic NEC (2000-2020). The main analyzed parameter was response rate treatment according RECIST criteria, depending on regimen used first line. overall survival additional parameter. RESULTS: 27 (13 initial stage IV disease and 14 progression after primary radical treatment). Ten 1st line underwent EP scheme, 4 — XELOX, 2 FOLFIRI, Irinotecan Cisplatin, 1 Samarium, Nivolumab, 5-FU-LV. Most often, effect (partial or stabilization) observed against background scheme 60% patients. median OS 7 months. CONCLUSION: use is preferred options for NEC. this group remains extremely low, new clinical trials are needed.